SurvivorNet // Connect

The new gold standard for HCP-focused media.

HEALTH CARE IS MOVING FORWARD FASTER THAN EVER - TOGETHER WE CAN MAKE SURE NO ONE IS LEFT BEHIND

HCP MENTAL HEALTH CRISIS

BREAKING SCIENCE

ADDRESSING RACIAL DISPARITIES

Latest News

Stay up to date on the latest news brought to you in collaboration with leading experts

View all Articles

To Treat Ovarian Cancer With PARP Inhibitors or Not: Factoring the Progression-Free Survival Benefit and Side Effects Into the Decision

PARP inhibitors like niraparib (Zejula) are an effective tool against ovarian cancer. The NOVA trial established that niraparib as maintenance therapy in platinum-sensitive patients significantly improved progression-free survival compared to placebo, regardless of women's BRCA or homologous recombination deficiency (HRD) status. Then, the PRIMA study found the treatment extended PFS in patients with newly diagnosed ovarian cancer, with or without HRD deficiency.

Learn More

In Head-to-Head Matchup with KRd, VRd Remains Gold Standard of Care in Multiple Myeloma

The three-drug combination of bortezomib, lenalidomide, and dexamethasone (VRd) has been the standard therapy for patients with newly diagnosed multiple myeloma. The ENDURANCE trial presented at ASCO was a head-to-head effort to determine whether adding the next-generation proteasome inhibitor on the block, carfilzomib, to lenalidomide and dexamethasone (KRd) might perform even better. In short, it didn't.

Learn More

Could Ibrutinib Combined With Other Targeted Therapies and Chemo Be ‘the Future’ of B-Cell Lymphoma Treatment?

New research is enhancing our understanding of ibrutinib -- a Bruton's tyrosine kinase (BTK) inhibitor used to treat several different types of lymphoma, including chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and mantle cell lymphoma. It has also produced positive responses in B-cell lymphoma, but is so far only used in patients with relapsed/refractory disease.

Learn More

Bispecific Antibodies Offer Lymphoma Patients a Promising New Therapeutic Option

Bispecific antibodies have exciting potential as a cancer therapy, due to their ability to simultaneously bind to two targets. Right now, this treatment is only available in investigational trials, but it has shown promising outcomes for patients with relapsed-refractory lymphoma who have already undergone a transplant, CAR T-cell therapy, or other lines of treatment.

Learn More

Upcoming Events

Sep. 22, 2020 4:00pm EST

Key Developments in Ovarian Cancer and Adjusting to COVID-19

This session qualifies for CME credit.

Learn More Register Now

Sep. 24, 2020 3:00pm EST

Key Developments in Multiple Myeloma and Adjusting to COVID-19

This session qualifies for CME credit.

Learn More Register Now

Past Events

Jul. 14, 2020 2:00pm EST

Key Developments in Multiple Myeloma in The Age of COVID-19 and Beyond

Thousands of physicians are struggling with new treatment protocols in the age Covid-19. On June 4th SurvivorNet held a collaborative conversation where opinion leaders addressed key topics.

Learn More View All Past Events

Our Mission

Progress through collective wisdom and collaborative energy

Oncologists around the country told us they needed a better way to stay up to date and find support, so we created SurvivorNet Connect. It's a digital platform dedicated to advancing the science and practice of oncology by providing health care providers with a fresh perspective on professional education.

Events & Conferences

Collaborative Workshops

Thought Leadership

“Bringing health care professionals together in a collaborative independent environment is one of the most important things we can do to make an outsize impact”

- Steve Alperin - Founder/CEO SurvivorNet